CLINICAL TRIALS PROFILE FOR MIVACRON

All Clinical Trials for MIVACRON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01906528 ↗	Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium	Completed	Oslo University Hospital	Phase 1	2013-03-01	Muscle relaxants are drugs providing muscle relaxation during surgical treatment. Previous studies have shown that males and females respond differently to this kind of drug. Our hypothesis is that males are more sensitive to the effect of Mivacurium (a muscle relaxant) than females, meaning that males need a lower blood concentration of the drug than females in order to obtain a given effect.
NCT01906528 ↗	Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium	Completed	University of California, San Francisco	Phase 1	2013-03-01	Muscle relaxants are drugs providing muscle relaxation during surgical treatment. Previous studies have shown that males and females respond differently to this kind of drug. Our hypothesis is that males are more sensitive to the effect of Mivacurium (a muscle relaxant) than females, meaning that males need a lower blood concentration of the drug than females in order to obtain a given effect.
NCT02117401 ↗	A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients	Completed	Jiangsu Nhwa Pharmaceutical Co., Ltd.	Phase 4	2012-01-01	To evaluate the effect and safety of mivacurium chloride in pediatric patients.
NCT02473601 ↗	Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis	Unknown status	Jiangsu Nhwa Pharmaceutical Co., Ltd.	Phase 2	2014-10-01	Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon
NCT02473601 ↗	Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis	Unknown status	Tang-Du Hospital	Phase 2	2014-10-01	Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon
NCT02664142 ↗	BIS Monitoring of the Depth of Anaesthesia in Children	Completed	University Hospital Ostrava	N/A	2015-06-01	General anaesthesia (GA) is, according to many definitions, the greatest gift presented to the medical art (S. B. Nuland). One of the aims of GA is to achieve the optimal depth of anaesthesia and rapid emergence from general anaesthesia. In order to achieve this goal, it is necessary to observe the clinical condition of the patient, and at the same time monitor the patient's overall condition. With the currently available options of GA management (e.g. use of intravenous anaesthetics, strong analgesics and modern volatile anaesthetics, in combination with various methods of topical anaesthesia) the importance of methods measuring the depth of GA increases. The depth of GA may be defined as a continuous progressive decreasing of the central nervous system, together with a decreased reactivity to stimuli. In the course of GA, perioperative awareness is detected in 0.1-0.2% of cases. Awakening during a surgical procedure may result in significant psychological complications (e.g. post-traumatic stress disorder), and the patient may suffer from a serious long-time disorder.

Clinical Trial Conditions for MIVACRON

Condition Name

Condition Name for MIVACRON
Intervention	Trials
Efficacy and Safety of Mivacurium Chloride for Pediatric Patients	1
General Surgery	1
Liver Dysfunction	1
Mivacurium	1

Condition MeSH

Condition MeSH for MIVACRON
Intervention	Trials
Paralysis	1
Liver Diseases	1
Liver Cirrhosis	1
Fibrosis	1

Clinical Trial Locations for MIVACRON

Trials by Country

Trials by Country for MIVACRON
Location	Trials
United States	1
Czechia	1
Czech Republic	1
China	1
Belgium	1

Trials by US State

Trials by US State for MIVACRON
Location	Trials
California	1

Clinical Trial Progress for MIVACRON

Clinical Trial Phase

Clinical Trial Phase for MIVACRON
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for MIVACRON
Clinical Trial Phase	Trials
Completed	4
Unknown status	1

Clinical Trial Sponsors for MIVACRON

Sponsor Name

Sponsor Name for MIVACRON
Sponsor	Trials
Jiangsu Nhwa Pharmaceutical Co., Ltd.	2
Oslo University Hospital	1
University of California, San Francisco	1

Sponsor Type

Sponsor Type for MIVACRON
Sponsor	Trials
Other	5
Industry	2

MIVACRON Market Analysis and Financial Projection

MIVACRON (Mivacurium Chloride): Clinical Trials, Market Analysis, and Projections

Introduction

MIVACRON, also known as mivacurium chloride, is a non-depolarizing neuromuscular blocking agent used in surgical procedures to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Here, we will delve into the clinical trials, market analysis, and projections for this drug.

Clinical Pharmacology and Use

MIVACRON is characterized by its rapid onset and short duration of action. It is a mixture of three stereoisomers, with the cis-trans and trans-trans isomers being the most potent, accounting for 92% to 96% of the mixture[1].

• Onset and Duration: The clinically effective duration of MIVACRON is one-third to one-half that of intermediate-acting agents and 2 to 2.5 times that of succinylcholine. The mean time for spontaneous recovery of the twitch response is about 6-8 minutes following initial doses[1].
• Dosage: The average ED95 (dose required to produce 95% suppression of the adductor pollicis muscle twitch response) is 0.07 mg/kg in adults receiving opioid/nitrous oxide/oxygen anesthesia[1].

Clinical Trials and Studies

While there are no recent clinical trials specifically focused on MIVACRON, existing studies provide valuable insights into its pharmacodynamics and pharmacokinetics.

• Pharmacokinetics: MIVACRON does not interconvert in vivo, and its pharmacokinetics is dose-proportional. The steady-state concentrations of the cis-trans and trans-trans isomers double when the infusion rate is increased from 5 to 10 mcg/kg/min[1].
• Variability in Patients: Studies have shown that variations in plasma cholinesterase activity do not significantly affect the duration of action. However, patients with renal impairment may experience a longer duration of action due to reduced clearance of the drug[1].

Market Analysis

Global Neuromuscular Blockade Drugs Market

The global neuromuscular blockade drugs market, which includes MIVACRON, is projected to grow significantly.

• Market Size: The market was valued at USD 5.23 billion in 2023 and is expected to reach USD 7.44 billion by 2031, with a CAGR of 4.50% during the forecast period of 2024 to 2031[2].
• Segmentation: The market is segmented by type (depolarizing, non-depolarizing), drugs (including MIVACRON), end-users (hospitals, homecare, specialty clinics), and distribution channels (hospital pharmacy, retail pharmacy, online pharmacies)[2].

Mivacurium Chloride Market

Specific to MIVACRON, the market is experiencing robust growth.

• Market Growth: The Mivacurium Chloride Market has shown rapid and considerable growth in recent years and is expected to continue this trend from 2023 to 2031. The market is categorized by type (purity 98%, purity 99%) and application (medicine, chemical, other)[5].
• Geographical Regions: The market is analyzed across various geographical regions including North America, Europe, Asia-Pacific, South America, and the Middle East and Africa[5].

Market Projections

Regional Insights

• North America: This region is expected to dominate the market due to its well-established healthcare infrastructure and increased focus on research and development activities related to muscle relaxants[2].
• Global Expansion: The positive momentum in market dynamics, coupled with anticipated continued expansion, indicates robust growth rates expected throughout the forecasted period[5].

Market Drivers and Challenges

• Drivers: The growth in the neuromuscular blockade drugs market is driven by the increasing demand for surgical procedures, advancements in healthcare infrastructure, and the presence of leading pharmaceutical companies[2].
• Challenges: Despite the growth, the market faces challenges such as interpatient variability in drug response, potential side effects, and the need for precise dosing to avoid complications[1].

Key Takeaways

• Clinical Use: MIVACRON is a non-depolarizing neuromuscular blocking agent with a rapid onset and short duration of action, making it suitable for various surgical procedures.
• Market Growth: The global neuromuscular blockade drugs market, including MIVACRON, is projected to grow significantly from 2023 to 2031.
• Regional Dominance: North America is expected to lead the market due to its advanced healthcare infrastructure and research activities.
• Market Segmentation: The market is segmented by type, drugs, end-users, and distribution channels, providing a comprehensive overview of market dynamics.

FAQs

What is MIVACRON used for?

MIVACRON is used as a non-depolarizing neuromuscular blocking agent to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.

How does MIVACRON compare to other neuromuscular blocking agents?

MIVACRON has a shorter duration of action compared to intermediate-acting agents but longer than ultra-short-acting agents like succinylcholine[1].

What are the key drivers of the MIVACRON market?

The market is driven by increasing demand for surgical procedures, advancements in healthcare infrastructure, and the presence of leading pharmaceutical companies[2].

What are the potential challenges in using MIVACRON?

Challenges include interpatient variability in drug response, potential side effects, and the need for precise dosing to avoid complications[1].

What is the projected market size for neuromuscular blockade drugs by 2031?

The global neuromuscular blockade drugs market is projected to reach USD 7.44 billion by 2031[2].

Sources

1. MIVACRON® Injection (mivacurium chloride) - FDA Label[1]
2. Global Neuromuscular Blockade Drugs Market - Data Bridge Market Research[2]
3. Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial[3]
4. Mivacurium Chloride - Drug Targets, Indications, Patents - Synapse[4]
5. Global Mivacurium Chloride Market Size, Scope And Forecast Report - Market Research Intellect[5]